Back

miR-425-5p Regulates Cellular Senescence Through Modulation of Retinoblastoma Protein Phosphorylation

Matai, L.; Haggenmueller, S.; Lee, J. D.; Slack, F. J.

2026-07-09 cell biology
10.64898/2026.06.15.732173 bioRxiv
Show abstract

MicroRNAs (miRNAs) are small non-coding RNAs that play critical roles in regulating cellular senescence and aging. Our recent studies identified a conserved C. elegans miRNA cluster (miR-229/64/65/66) that is required for normal adult lifespan, with overexpression significantly extending longevity. Notably, cel-miR-229 is evolutionarily conserved in humans, with hsa-miR-425 sharing an identical seed sequence. Here, we investigated the role of miR-425 in mammalian cellular senescence. We found that miR-425 expression is markedly reduced in pharmacologically induced senescence in human lung cancer cells. Restoration of miR-425 expression attenuates senescence and suppresses the expression of senescence-associated secretory phenotype (SASP) cytokines following senescence induction. We further observed that miR-425 levels decline during replicative senescence, whereas stable overexpression in WI-38 fibroblasts delays senescence accumulation and preserves proliferative capacity. Mechanistically, miR-425 suppresses TGF-{beta} signaling, leading to reduced expression of the cyclin-dependent kinase inhibitor p21/CDKN1A and increased phosphorylation of the retinoblastoma (RB) protein, thereby promoting cell-cycle progression. We further identify PPP2CB, the catalytic subunit of protein phosphatase 2A (PP2A), as a direct target of miR-425. PPP2CB expression is downregulated in miR-425-5p overexpressing cells, even under senescence induction. Knockdown of PPP2CB using siRNA phenocopies the effects of miR-425 overexpression, reducing senescence, enhancing proliferative potential, and increasing RB phosphorylation. Collectively, our findings identify miR-425 as a conserved regulator of cellular senescence that acts through upregulation of RB phosphorylation. These results establish a novel miR-425-PPP2CB-RB regulatory axis controlling proliferation and senescence and suggest miR-425 as a potential therapeutic target for mitigating senescence to promote extended health span.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Aging Cell
165 papers in training set
Top 0.1%
38.6%
2
Cell Death & Disease
21 papers in training set
Top 0.1%
5.4%
3
Molecular and Cellular Biology
47 papers in training set
Top 0.1%
5.0%
4
PLOS Genetics
862 papers in training set
Top 3%
4.7%
50% of probability mass above
5
Aging
75 papers in training set
Top 0.4%
3.9%
6
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 15%
3.4%
7
GeroScience
109 papers in training set
Top 0.8%
3.2%
8
npj Aging
22 papers in training set
Top 0.2%
2.7%
9
Cell Reports
1498 papers in training set
Top 17%
2.1%
10
Science Advances
1243 papers in training set
Top 20%
1.7%
11
PLOS ONE
5266 papers in training set
Top 49%
1.7%
12
Scientific Reports
3612 papers in training set
Top 57%
1.6%
13
Nature Communications
5641 papers in training set
Top 48%
1.5%
14
EMBO Reports
263 papers in training set
Top 4%
1.5%
15
eLife
5828 papers in training set
Top 55%
1.3%
16
G3: Genes|Genomes|Genetics
35 papers in training set
Top 0.3%
1.1%
17
Nucleic Acids Research
1281 papers in training set
Top 11%
1.1%
18
Biochemical Journal
91 papers in training set
Top 1%
1.1%
19
Journal of Biological Chemistry
690 papers in training set
Top 8%
1.1%
20
Communications Biology
993 papers in training set
Top 23%
1.1%
21
Cellular and Molecular Life Sciences
96 papers in training set
Top 2%
1.0%
22
The EMBO Journal
309 papers in training set
Top 7%
0.8%
23
Journal of Cell Science
393 papers in training set
Top 5%
0.8%
24
JCI Insight
277 papers in training set
Top 9%
0.6%
25
Journal of Biomedical Science
17 papers in training set
Top 0.5%
0.6%
26
Molecular Cell
350 papers in training set
Top 6%
0.6%
27
Cell Chemical Biology
94 papers in training set
Top 2%
0.6%
28
Life Science Alliance
285 papers in training set
Top 10%
0.6%